

# OPAL - Cross-sectional study assessing the prevalence of co-addictions in subjects receiving opioid substitution treatment: determination of the clinical and pharmacological profile

Head :Grall-Bronnec Marie, Addiction department of the CHU de Nantes / UIC 18 Clinical Investigation Unit:  
Behavioural addictions and complex mood disorders / EA 4275 SPHERE

Last update : 02/17/2020 | Version : 1 | ID : 73282

## General

### Identification

Detailed name Cross-sectional study assessing the prevalence of co-addictions in subjects receiving opioid substitution treatment: determination of the clinical and pharmacological profile

Sign or acronym OPAL

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL: authorisation No. 913237 / CCTIRS: No. 13.223

### General Aspects

Medical area Biology  
Psychology and psychiatry

Health determinants Addictions  
Genetic

Keywords Opioid dependence, opioid substitution treatment, psychoactive substance, pharmacokinetics, pharmacogenetics, polymorphism, cytochrome P450 2D6, addictions, pathological gambling

### Scientific investigator(s) (Contact)

Name of the director Grall-Bronnec

Surname Marie

Address IFAC  
Batiment Louis Philippe  
Hopital St Jacques  
85 rue St Jacques  
44 093 Nantes cedex 01

Phone + 33 (0)2 40 84 61 16

Email	marie.bronnec@chu-nantes.fr
Unit	Addiction department of the CHU de Nantes / UIC 18 Clinical Investigation Unit: Behavioural addictions and complex mood disorders / EA 4275 SPHERE
Organization	Chu de Nantes

## Collaborations

Participation in projects, networks and consortia Yes

Details Multicentric study in collaboration with the CHU de Brest, CHU d'Angers, CH de Morlaix, CH G. Régnier de Rennes, CSAPA "Le Triangle" (Nantes), "La métairie" (La Roche S / Yon) And "La Rose des Vents" (St Nazaire), the SMPR in Nantes and the Addictions Network of the Nantes Region (RTRN)

## Funding

Funding status Public

Details Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA)

## Governance of the database

Sponsor(s) or organisation(s) responsible Chu de Nantes

Organisation status Public

Presence of scientific or steering committees No

## Additional contact

## Main features

## Type of database

Type of database Study databases

Study databases (details) Not-repeated cross-sectional studies (except case control studies)

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	The study will focus on patients with a prescribed OST due to opioid dependence, whether the OST is methadone, buprenorphine (+/- naloxone) or a morphine-based drug. Recruitment is multicentric (10 centres in the western region participated in this study)

## Database objective

Main objective	assess the current prevalence of addictive comorbidities in opioid-dependent subjects who have been receiving opioid substitution therapy (OST) for at least 6 months.
Inclusion criteria	<p>Adult</p> <p>Treatment with methadone or buprenorphine (+/- naloxone) or morphine as a substitute, prescribed for opioid dependence</p> <p>OST established for at least 6 months</p> <p>Incarceration of less than one month if monitored by a Regional Medical and Psychological Service (SMPR) in prison</p> <p>Good understanding of French, knowing how to read and write it.</p>

## Population type

Age	<p>Adulthood (19 to 24 years)</p> <p>Adulthood (25 to 44 years)</p> <p>Adulthood (45 to 64 years)</p> <p>Elderly (65 to 79 years)</p>
Population covered	Sick population
Pathology	V - Mental and behavioural disorders
Gender	<p>Male</p> <p>Woman</p>
Geography area	National
Detail of the geography area	Nantes, Brest, Morlaix, Angers, Rennes, St Nazaire

## Data collection

## Dates

Date of first collection (YYYY or MM/YYYY)	11/2013
--	---------

Date of last collection (YYYY or MM/YYYY)	2016
---	------

## Size of the database

Size of the database (number of individuals)	< 500 individuals
--	-------------------

Details of the number of individuals	263
--------------------------------------	-----

## Data

Database activity	Data collection completed
-------------------	---------------------------

Type of data collected	Clinical data Declarative data
------------------------	-----------------------------------

Clinical data (detail)	Direct physical measures
------------------------	--------------------------

Declarative data (detail)	Paper self-questionnaire Face to face interview
---------------------------	--

Presence of a biobank	Yes
-----------------------	-----

Contents of biobank	Whole blood
---------------------	-------------

Health parameters studied	Health event/morbidity
---------------------------	------------------------

## Procedures

Data collection method	collection of data in consultation by the physician and/or nurse
------------------------	--

Quality procedure(s) used	Verification of data by a Clinical Study Technician and the consistency of data by the data cell when entering it into the computer database
---------------------------	--

Participant monitoring	No
------------------------	----

Followed pathology	
--------------------	--

Links to administrative sources	No
---------------------------------	----

## Promotion and access

### Promotion

## Access

Terms of data access (charter for data provision, format of data, availability delay)

Contact the scientist in charge.

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only